Full Text View
Tabular View
No Study Results Posted
Related Studies
Generic vs. Name-Brand Levothyroxine
This study is currently recruiting participants.
Verified by Children's Hospital Boston, May 2008
First Received: November 21, 2006   Last Updated: May 9, 2008   History of Changes
Sponsored by: Children's Hospital Boston
Information provided by: Children's Hospital Boston
ClinicalTrials.gov Identifier: NCT00403390
  Purpose

This study compares two different brands of thyroxine (thyroid hormone). Currently, pharmacists may be substituting generic formulations of thyroid hormone without your doctor knowing about this. Although a small difference in thyroid function is not significant in most healthy children, adolescents and adults, in infants and toddlers even a small difference in thyroid function can have important harmful consequences on brain development. The purpose of the present study is to learn whether the difference between brands of thyroid hormone that are currently being substituted is sufficient to cause a difference in thyroid function.


Condition Intervention Phase
Congenital Hypothyroidism
Hypothyroidism
Drug: Levothyroxine versus Levothyroxine
Phase III

Study Type: Interventional
Study Design: Treatment, Randomized, Open Label, Active Control, Crossover Assignment, Bio-equivalence Study
Official Title: Generic vs. Name-Brand Levothyroxine: Assessment of Bioequivalence Using TSH as a Marker in Children With Permanent Hypothyroidism

Resource links provided by NLM:


Further study details as provided by Children's Hospital Boston:

Primary Outcome Measures:
  • Thyroid Stimulating Hormone Measure [ Time Frame: 3 points over 16 weeks ] [ Designated as safety issue: No ]

Estimated Enrollment: 40
Study Start Date: June 2006
Estimated Study Completion Date: March 2009
Estimated Primary Completion Date: December 2008 (Final data collection date for primary outcome measure)
Intervention Details:
    Drug: Levothyroxine versus Levothyroxine
    Randomized crossover study using 8 weeks of one form of levothyroxine, then 8 weeks of the other form of levothyroxine. The dose of medication does not change throughout the duration of the study.
Detailed Description:

This study is an unblinded, randomized controlled cross-over study, which involves taking 2 different forms of levothyroxine sequentially over a 16 week period. Subjects will have a total of 3 visits over this time period. At the first visit, subjects are randomized to receive either generic (Sandoz) levothyroxine or Synthroid (Abbott) brand of levothyroxine. Blood is drawn for baseline thyroid function studies and other markers which are influenced by thyroid hormone at each visit. The second visit is the cross-over visit, and the final visit is a close-out visit, after which each subject will resume taking their previous formulation of levothyroxine.

  Eligibility

Ages Eligible for Study:   3 Years to 18 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Age between 3 and 18 years
  • Diagnosis of Congenital Hypothyroidism with initial TSH > 100
  • Ability to understand directions and follow all instructions

Exclusion Criteria:

  • Not on any drug interfering with absorption of levothyroxine
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00403390

Contacts
Contact: Jeremi M Carswell, MD 617-355-6168 Jeremi.Carswell@childrens.harvard.edu

Locations
United States, Massachusetts
Children's Hospital Boston Recruiting
Boston, Massachusetts, United States, 02115
Sponsors and Collaborators
Children's Hospital Boston
Investigators
Principal Investigator: Rosalind S Brown, MD Children's Hospital Boston
  More Information

No publications provided

Responsible Party: Children's Hospital Boston ( Rosalind Brown, MD Clinical Trials Director )
Study ID Numbers: 05-11-146
Study First Received: November 21, 2006
Last Updated: May 9, 2008
ClinicalTrials.gov Identifier: NCT00403390     History of Changes
Health Authority: United States: Institutional Review Board

Study placed in the following topic categories:
Bone Diseases, Endocrine
Dwarfism
Cretinism
Genetic Diseases, Inborn
Musculoskeletal Diseases
Congenital Hypothyroidism
Bone Diseases, Developmental
Endocrine System Diseases
Hypothyroidism
Endocrinopathy
Bone Diseases
Thyroid Diseases

Additional relevant MeSH terms:
Bone Diseases, Endocrine
Dwarfism
Genetic Diseases, Inborn
Musculoskeletal Diseases
Congenital Hypothyroidism
Bone Diseases, Developmental
Endocrine System Diseases
Hypothyroidism
Bone Diseases
Thyroid Diseases

ClinicalTrials.gov processed this record on July 06, 2009